June 09, 2020
Outcomes of the EMA's Committee for Medicinal Products for Human Use May 2020 meeting published
On May 29, 2020, the European Medicines Agency (EMA) has published outcomes of the meeting of the Committee for Medicinal Products for Human Use (CHMP). Eight (8) positive opinions on new medicines, five (5) recommendations on extensions of therapeutic indications, and two (2) withdrawn applications for new medicines were made.

Positive opinions on new medicines:

  • The new Ebola vaccine consisting of two components - Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo)
  • Hepcludex (bulevirtide)
  • Piqray (alpelisib)
  • Rozlytrek (entrectinib)
  • Xenleta (lefamulin)
  • Zercepac (trastuzumab)
  • Apixaban Accord (apixaban)
There were no negative recommendations on new medicines.

Positive opinions on extensions of therapeutic indications were granted to Invokana, Lynparza, Ofev, Sivextro, and Taltz.

Applications for initial marketing authorisations for Erlotinib Accord (erlotinib) and Fingolimod Mylan (fingolimod) have been withdrawn.

The CHMP meetings are held each month.

See all the details about this meeting and other details of the recommendations in English here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)